Please contact our sales representative to learn more information about this reagents.
Background
Daratumumab, sold under the brand name Darzalex, is an anti-cancer medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.